This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Merrimack Pharmaceuticals Inc (MACK)

NASDAQ: Health Care

Company Balance Sheet
Dec 2014 Dec 2013 Dec 2012 Dec 2011
Assets
Cash and Equivalents 35.69M 65.09M 37.71M 50.45M
Receivables 3.31M 5.86M 9.27M 7.43M
Inventories 0.00 0.00 0.00 0.00
Other Current Assets 0.00 0.00 0.00 0.00
Total Current Assets 132.10M 166.64M 128.30M 65.59M
Property, Plant & Equipment, Gross 38.64M 34.91M 25.27M 22.34M
Accumulated Depreciation & Depletion 24.14M 21.55M 18.97M 16.13M
Property, Plant & Equipment, Net 14.50M 13.36M 6.30M 6.21M
Intangibles 7.72M 8.04M 9.18M 9.50M
Other Non-Current Assets 728.00K 759.00K 1.60M 404.00K
Total Non-Current Assets 26.56M 25.77M 20.67M 19.71M
Liabilities & Shareholder Equity
Total Assets 158.66M 192.42M 148.97M 85.30M
Accounts Payable 2.51M 1.89M 283.00K 4.66M
Short Term Debt 13.35M 8.25M 2.37M 48.00K
Other Current Liabilities 1.30M 1.36M 1.08M 0.00
Total Current Liabilities 111.14M 57.73M 38.52M 26.15M
Long Term Debt 106.81M 103.43M 37.48M 0.00
Deferred Income Taxes 496.00K 507.00K 755.00K 1.27M
Other Non-Current Liabilities 42.28M 73.88M 78.64M 79.57M
Minority Interest -268.00K 240.00K -477.00K -453.00K
Total Non-Current Liabilities 149.65M 178.15M 116.97M 349.64M
Total Liabilities 260.80M 235.88M 155.49M 375.79M
Preferred Stock Equity 0.00 0.00 0.00 0.00
Common Stock Equity -102.14M -43.46M -6.52M -290.49M
Common Par 1.07M 1.02M 958.00K 118.00K
Additional Paid In Capital 552.04M 527.78M 434.68M 60.23M
Cumulative Translation Adjustment 0.00 0.00 0.00 0.00
Retained Earnings -655.17M -572.24M -442.12M -350.84M
Treasury Stock 0.00 0.00 0.00 0.00
Other Equity Adjustments -74.00K -24.00K -38.00K 0.00
Total Capitalization 4.67M 59.96M 30.96M -290.49M
Total Equity -102.14M -43.46M -6.52M -290.49M
Total Liabilities & Stock Equity 158.66M 192.42M 148.97M 85.30M
Total Common Shares Outstanding 106.70M 102.52M 95.82M 92.40M
Preferred Shares 0.00 0.00 0.00 0.00
Treasury Shares 0.00 0.00 0.00 0.00
Basic Weighted Shares Outstanding 104.41M 98.92M 72.83M 11.34M
Diluted Weighted Shares Outstanding 104.41M 98.92M 72.83M 11.34M
Number of Employees 306 254 230 218
Number of Part-Time Employees 0 0 0 0
MACK News

MACK Merrimack Pharmaceuticals Inc

Analysts Ratings for MACK

Rating Current 1-Mo Ago 2-Mo Ago 3-Mo Ago
Strong Buy 6 5 5 5
Moderate Buy 0 0 0 0
Hold 0 0 0 0
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0
GET MACK ANALYST REPORT

Brokerage Partners

MACK Chatter

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
Real Money Pro

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Trifecta Stocks

Trifecta Stocks analyzes over 4,000 equities weekly to find the elite 1% of stocks that pass rigorous quantitative, fundamental and technical tests.

Product Features:
  • Model portfolio
  • Trade alerts
  • Recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Growth Seeker

Bryan Ashenberg, using sophisticated stock screening and fundamental research, identifies potentially explosive small and mid-cap stocks.

Product Features:
  • Model portfolio
  • Small-cap and mid-cap focus
  • Intraday trade alerts
  • Weekly roundups
Options Profits

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
Top Rated Stocks Top Rated Funds Top Rated ETFs